using pros to measure secondary endpoints
TRANSCRIPT
![Page 1: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/1.jpg)
The Diabetes Health Profile: Using PRO Measures to Support
EndpointsPRO/COA Summit
Philadelphia 6th May 2014
Dr Keith Meadows
![Page 2: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/2.jpg)
Dr. Keith Meadows PhDPhD – DHP Research
—Keith is a Health Psychologist with over 25 years of research experience and has held a number of senior academic and UK NHS research positions.
Prior to setting up DHP Research & Consultancy, Keith was Associate Director of the North East London Consortium for Research & Development (NELCRAD). Keith's specialist areas include, the psychological impact of living with diabetes and patient reported outcome measurement.
Keith has published widely, avid presenter papers at major conferences.
![Page 3: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/3.jpg)
• Well-conducted randomized controlled trials are instrumental in providing vital data on safety and efficacy of new molecules under consideration for approval
• Acquiring such data involves huge cost and focused scientific effort
• Selection and reporting of endpoints of a therapy is essential to assess the effect(s) of an intervention on overall disease control
Introduction
![Page 4: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/4.jpg)
• Why it’s important to have a pre-defined secondary endpoint
• What is the relationship between primary and secondary endpoints
• Selecting the appropriate PRO to achieve identified endpoints
Setting the scene
![Page 5: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/5.jpg)
Diabetes is a common hormonal problem that if untreated can lead to diabetes complications such as:
What is Diabetes?
diabetic neuropathy
heart problems
retinopathyamputation
kidney failure
blindness
![Page 6: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/6.jpg)
• Type 1 diabetes (insulin-dependent) requires insulin to treat, is typically developed as a child or young adult, and is a disease that destroys pancreatic cells resulting in loss of insulin production.
• Type 2 diabetes (non-insulin dependent diabetes) is considerably more common and typically affects people over the age of 45, who are also overweight. Those suffering from type 2 are unable to produce enough insulin, and sugar builds up in the bloodstream.
What is Diabetes?
![Page 7: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/7.jpg)
To maintain blood glucose levels within the normal range (HbA1c <7.0%)
The management of diabetes
![Page 8: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/8.jpg)
10%ANXIETY aggression
Therapy non adherence
POOR QUALITY OF LIFE
Disruption to social and professional life
Eating problems
The Psychological Impact of Living with Diabetes
![Page 9: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/9.jpg)
A PRO Measurement Strategy
Identify primary and secondary outcomes relevant to treatment or intervention
Identify key treatment effects and outcomes
Develop endpoint model
Select appropriate Patient reported outcome (PRO) measure
![Page 10: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/10.jpg)
“If the endpoint is not meaningful, then the result will not really have an impact.”
Niko Andre - Roche
![Page 11: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/11.jpg)
The ideal clinical and statistical situation for design of confirmatory clinical trials is to prospectively specify a single primary endpoint that:
• characterizes disease under study • enables efficient evaluation of treatment
effect
The ideal endpoint
![Page 12: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/12.jpg)
• Clinical relevance: must focus directly on study’s primary objective, mechanism of action of intervention and impact on patients’ well-being
• Reliability: must be capable of being assessed in all subjects consistently
• Validity of comparison: must be ascertainable and classifiable to allow comparison between treatment groups
Desirable features of the primary endpoint
![Page 13: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/13.jpg)
Primary endpoints• Reduction in post-prandial glucose,
or high blood sugar levels after meals
• Reduction of A1C levels at six months
• Reduction of risk of cardiovascular death, myocardial infarction, and stroke
• reductions in fasting plasma glucose
Secondary endpoints• Reduction in rate of overall
hypoglycaemic events
• Treatment satisfaction
• Improved health status• Improved health-related
quality of life
• Reduced fear of hypoglycaemic episodes
Typical endpoints in a diabetes clinical trial
![Page 14: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/14.jpg)
• Secondary (components of composite) endpoints serve a number of important roles
• These endpoints, although not considered primary, are considered important to prescribing physicians in helping to identify the ideal treatment for each of their patients
• Key endpoint, critical on their own (e.g., reduction in hypoglycaemia)
• Supportive, provide more comprehensive understanding of drug effect
• Findings based on secondary endpoints do not generally lead to labelling claim if primary objective not met
The importance of pre-defined secondary endpoints
![Page 15: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/15.jpg)
“Successful PRO labelling claims are typically based on primary endpoints assessing signs and symptoms. Based on this research, studies with PROs as primary endpoints are far more likely to facilitate positive regulatory review and acceptance of PROs in support of labelling claims.
Although inclusion of PROs as non-primary endpoints in clinical trials has its challenges, recent PRO labels granted by the FDA show that they can indeed be candidates for PRO labelling claims as long as they are supported by evidence.”Ari Gnanasakthy et al 2013
![Page 16: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/16.jpg)
The relationship between primary and secondary endpoints
Reduction of A1C levels at six
months
Improved health-related quality of
life
Reduced fear of hypoglycaemic
episodes
Reduction in rate of overall
hypoglycaemic events
![Page 17: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/17.jpg)
Common practice
• Often based on previous use in other studies
• Name of PRO appears to be appropriate
• PRO (health status, QoL, HRQoL, well-being) concepts used interchangeably
PRO Measurement concepts
• Health status = quality of health e.g. functional impairment (SF-36)
• QoL = individual’s subjective evaluation of psychological, physical & social aspects of their life
• HRQoL = treatment and illness perceived as impacting on areas of life considered important
Selecting the Appropriate PRO
![Page 18: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/18.jpg)
Generic
• Suitable for the general population
• Comparisons with other conditions/disease groups
• Content may be redundant for certain condition/illnesses
• Not sensitive to detecting disease-specific issues
Condition-specific
• Specific to disease group
• Sensitive to detecting clinically significant changes
• Content relevant to target group
• Cannot compare with general population
Generic and Condition-specific: Making the Choice
![Page 19: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/19.jpg)
Characteristics of the individual
Biological & psychological
status
Symptom status
General health
perceptions
Functional status
Overall quality of life (QoL)
Characteristics of the environment
The Wilson-Cleary Conceptual model of HRQoL
Wilson IB and Cleary PD, Linking clinical variables with health-related quality of life. JAMA 273: pp59-65. 1995
![Page 20: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/20.jpg)
Item 1Item 2Item 3Item 4Item 5
Item 6Item 7Item 8Item 9
Generic and Condition-specific: Making the Choice
Item 6Item 7Item 8
Item 9Item 10
Item 6Item 7Item 8Item 9
Item 10Item 11Item 12
Domain Ascore
Domain Bscore
Domain Cscore
• Also known as a content map/ measurement model
• Specifies how items fit together in a PRO to produce a domain score
• Developed during development of PRO – focus groups/literature review, patient interviews
• Validated through a process of psychometric validation
• FDA requirements specify that labelling of a domain has to be meaningful with respect to all the items in the domain
A Simplified PRO Conceptual Framework
![Page 21: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/21.jpg)
Simplified Endpoint Model for Reducing Hypoglycaemia
Desired claims:
1. Reduction in symptoms
2. Improvement in HRQoL
Reduction in hypoglycaemia
Improved HRQoL
MeasureSymptom checklist• Sweating• Fatigue• Trembling• Dizziness
• Lowered anxiety• Improved mood• Increased social
activity
MeasurePRO Measure
![Page 22: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/22.jpg)
EndpointModel
Clinical Endpoints
PRO Endpoints
PRO Conceptual
Framework(s)
Interrelationship between PRO Conceptual Framework, Endpoint Model and Label/Value Claim
ConceptualModel
Label/value claim
![Page 23: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/23.jpg)
The Diabetes Health ProfileThe conceptual model
diabetes
![Page 24: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/24.jpg)
The Diabetes Health Profile (DHP)
Representing research spanning over 20 years, the Diabetes Health Profile (DHP) is a diabetes-specific patient reported outcome measure (PROM) developed in accordance with FDA Guidelines and available in 29 languages.
![Page 25: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/25.jpg)
Conceptual Framework for the DHP-1 and DHP-18
![Page 26: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/26.jpg)
The Diabetes Health Profile (DHP-18)
![Page 27: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/27.jpg)
The Diabetes Health Profile (DHP-18)
![Page 28: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/28.jpg)
Interpreting the Diabetes Health Profile
The minimally important difference (MID) is the smallest score difference on the Diabetes Health Profile that represents the minimal clinically significant difference.
The required MID change in score for the DHP-18 domains
Psychological distress
7 – 11
Barriers to activity
Disinhibited eating
6.5 – 9.9
7.5 – 11.4
Investigating the minimally important difference of the Diabetes Health Profile (DHP-18) and the EQ-5D and SF-6D in a UK diabetes mellitus population. Mulhern B and Meadows K. Health 5: 1045-1054,2013
![Page 29: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/29.jpg)
Previous and Current Users of the DHP
10,000Type 1 & Type 2
RespondentsHave completed the
DHP-1 / DHP-18
More than
![Page 30: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/30.jpg)
PROs among patients with type 2 diabetes using exenatide twice daily or insulin in clinical practice.• A prospective 24-month observational study in
six- European countries• Exenatide (BID) (N=1114) or insulin (N=1274)Reaney et al Quality of Life Outcomes 2013, 11. 217
Diabetes – A case study using the DHP-18
![Page 31: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/31.jpg)
Composite clinical endpoint:• No weight gain ≤ 1kg• Glycaeted haemoglobin
(HbA1c <7%)• No hypoglycaemia
PRO endpoints• HRQoL (DHP-18)• Emotional distress
(Hospital Anxiety & Depression Scale)
• EuroQol (EQ-5D)
Diabetes – A case study using the DHP-18
![Page 32: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/32.jpg)
Key findings:Patients meeting the composite criteria (HbA1c <7.0%, no weight gain, no hypoglycaemia)• Higher improvements in EQ-5D index and VAS
scores• Numerically higher DHP-18 scores over the 24-
months
Diabetes – A case study using the DHP-18
![Page 34: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/34.jpg)
What does this case study demonstrate?
• PROs not adversely affected by insulin therapy initiation
• PRO data may aid appropriate treatment selection for individual patients
Diabetes – A case study using the DHP-18
![Page 35: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/35.jpg)
• Selection and reporting of endpoints of a therapy is essential to assess the effect(s) of an intervention on overall disease control
• Selecting the appropriate PRO to support endpoints must be based on a clearly defined measurement strategy and an understanding of the relationship between primary and secondary endpoints
• Secondary endpoints provide more comprehensive understanding of drug and treatment effect
• Findings based on secondary endpoints do not generally lead to labelling claim if primary objective not met
Summary
![Page 36: Using PROs to measure secondary endpoints](https://reader033.vdocuments.site/reader033/viewer/2022052905/5585b848d8b42a49548b4b67/html5/thumbnails/36.jpg)
Thank you
Q & A